Global initiative for asthma management and prevention - GINA 2006;Krankheitskontrolle als therapieprinzip beim asthma bronchiale

Pneumologie

Volumn 61, Issue 5, 2007, Pages 295-304

  Kroegel, Claus ^a,b  

^a Medizinische Klinik I   (Germany)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; CROMOGLYCATE DISODIUM; GLUCOCORTICOID; LEUKOTRIENE RECEPTOR BLOCKING AGENT; NEDOCROMIL; OMALIZUMAB; THEOPHYLLINE DERIVATIVE;

ASTHMA; CLINICAL PRACTICE; DISEASE CLASSIFICATION; DISEASE EXACERBATION; DISEASE SEVERITY; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; MILD INTERMITTENT ASTHMA; MILD PERSISTENT ASTHMA; MODERATE PERSISTENT ASTHMA; PEAK EXPIRATORY FLOW; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SEVERE PERSISTENT ASTHMA;

ANTI-ASTHMATIC AGENTS; ASTHMA; HUMANS; WORLD HEALTH;

EID: 34447506170     PISSN: 09348387     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-959180     Document Type: Review

References (74)

1. Wettengel R, Berdel D, Celga U et al. Empfehlungen der Deutschen Atemwegsliga zum Asthmamanagement bei Erwachsenen und bei Kindern. Med Klin 1994; 89: 57-67
2. Buhl R, Berdel D, Criée CP et al. Leitlinie zur Diagnostik und Therapie von Patienten mit Asthma bronchiale 2005. Pneumologie 2006; 60: 139-179
3. Boulet LP, Becker A, Bérubé D et al. The asthma consensus report 1999. CMAJ 1999; 161 (11 Suppl.): S1-S6
4. Global Initiative for Asthma. GINA workshop report, global strategy for asthma management and prevention. Available at: http//www.ginastma.org. Letzter Zugang 22. Dezember 2006
5. National Asthma Education and Prevention Program. (1997) Expert panel report 2: guidelines for the diagnosis and management of asthma. National Institutes of Health. Bethesda, MD: publication,: No. 97-4051
6. Wettengel R, Bredel D, Hofmann D et al. Empfehlungen zur Asthmatherapie von Kindern und Erwachsenen. Pneumologie 1998; 52: 591-601
7. Crim C. Clinical practice guidelines vesus actual clinical practice: the asthma paradigm. Chest 2000; 118 (2 Suppl): 62S-64S
8. Doerschug KC, Peterson MW, Dayton CS et al. Asthma guidelines: an assessment of physician understanding and practice. Am J Respir Crit Care Med 1999; 159: 1735-1741
9. Freeman AC, Sweeney K. Why general practitioners do not implement evidence: qualitative study. BMJ 2001; 323: 1100-1102
10. Sawyer G, Miles J, Lewis S et al. Classification of asthma severity: should the international guidelines be changed? Clin Exp Allergy 1998; 28: 1565-1570
11. Vollmer WM, O'Hollaren M, Ettinger KM et al. Specialty differences in the management of asthma. A cross-sectional assessment of allergists' patients and generalists' patients in a large HMO. Arch Intern Med 1997; 157: 1201-1208
12. Graham LM. Classifying asthma. Chest 2006; 130 (1 Suppl): 13S-20S
13. Miller MK, Johnson C, Miller DP et al. Severity assessment in asthma: An evolving concept. J Allergy Clin Immunol 2005; 116: 990-995
14. Price D, Thomas M. Breaking new ground: challenging existing asthma guidelines. BMC Pulm Med 2006; 6 (Suppl 1): 1-8
15. Kroegel C. Vorschläge zur Systematisierung der nationalen Richtlinien für die Behandlung des Asthma bronchiale im Erwachsenenalter in Deutschland. Med Klinik 1997; 92: 621-625
16. Kroegel C. Asthma bronchiale. Pathogenetische Grundlagen, Diagnostik und Therapie. Stuttgart, New York: Georg Thieme Verlag, 2. überarbeitete und erweiterte Auflage, 2002
17. Kroegel C. Asthmatherapie - Leitfaden einer pathogenetisch begründeten Behandlung. Stuttgart-Steinen: Zett Verlag, 2. überarbeitete und erweiterte Auflage, 2005
18. 1 and PEF in the assessment of the severity of airways obstruction. Respirology 2002; 7: 333-337
19. Chipps BE. Determinants of asthma and its clinical course. Ann Allergy Asthma Immunol 2004; 93: 309-915
20. Kotaniemi-Syrjänen A, Reijonen TM, Korhonen K et al. Sodium cromoglycate therapy in wheezing infants: preliminary evidence of beneficial outcome at early school age. Pediatrics International 2005; 47: 627-634
21. Luskin AT. What the asthma end points we know and love do and do not tell us. 9: J Allergy Clin Immunol 2005; 115 (4 Suppl): S539-545
22. Mutius E von. Influences in allergy: epidemiology and the environment. J Allergy Clin Immunol 2004; 113: 373-379
23. Rennard SI, Farmer SG. Exacerbations and progression of disease in asthma and chronic obstructive pulmonary disease. Proc Am Thorac Soc 2004; 1: 88-92
24. Yawn BP, Molen T van der, Humbert M. Asthma management: Are GINA guidelines appropriate for daily clinical practice? Prim Care Respir J 2005; 14: 294-302
25. Baker KM Jr, Brand DA, Hen J. Classifying asthma: disagreement among specialists. Chest 2003; 124: 2156-2163
26. Bateman ED, Boushey HA, Bousquet J et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 2004; 170: 836-844
27. Wenzel SE. Severe asthma in adults. Am J Respir Crit Care Med 2005; 172: 149-160
28. O'Byrne PM, Barnes PJ, Rodriguez-Roisin R et al. Low-dose inhaled budesonide and formoterol in mild persistent asthma, the OPTIMA randomized trial. Am J Respir Crit Care Med 2001; 164 (8 Pt 1): 1392-1397
29. Pauwels RA, Pedersen S, Busse WW et al. Early intervention with budesonide in mild persistent asthma: a randomized, double-blind trial. Lancet 2003; 361 (9363): 1071-1076
30. Zeiger RS, Baker JW, Kaplan MS et al. Variability of symptoms in mild persistent asthma: baseline data from the MIAMI study. Respir Med 2004; 98: 898-905
31. Using beta2-stimulants in asthma. Drug Ther Bull 1997; 35: 1-4
32. Godfrey S, Bar-Ylshay E. Exercised-induced asthma revisited. Respir Med 1993; 87: 331-344
33. Leff JA, Busse WW, Pearlman D et al. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. N Engl J Med 1998; 339: 147-152
34. Spooner CH, Saunders LD, Rowe BH. Nedocromil sodium for preventing exercise-induced bronchoconstriction. Cochrane Database Syst Rev 2000; (2): CD 001183
35. Ram FS, Robinson SM, Black PN. Physical training for asthma. Cochrane Database Syst Rev 2000; (2): CD 001116
36. Reiff DB, Choudry NB, Pride NB et al. The effect of prolonged submaximal warm-up exercise on exercise-induced asthma. Am Rev Respir Dis 1989; 139: 479-484
37. Adams NP, Bestall JB, Malouf R et al. Inhaled beclomethasone versus placebo for chronic asthma. Cochrane Database Syst Rev 2005; (1): CD002738
38. Kroegel C, Reißig A, Walter R et al. Inhalierbare Glucocorticoide der dritten Generation. Ciclesonid Arzneimittelth 2006; 24: 73-83
39. Barnes NC, Miller CJ. Effect of leucotriene receptor antagonist therapy on the risk of asthma exacerbations in patients with mild to moderate asthma: an integrated analysis of zifirlukast trials. Thorax 2000; 55: 478-483
40. Bleeker ER, Welch MJ, Weinstein SF et al. Low-dose inhaled fluticasone propionate versus oral zafirlukast in the treatment of persistent asthma. J Allergy Clin Immunol 2000; 105 (6 Pt 1): 1123-1129
41. Drazen JM, Isreal E, O'Byrne PM. Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med 1999; 340: 197-206
42. Philip G, Nayak AS, Berger WE et al. The effect of montelukast on rhinitis symptoms in patients with asthma and seasonal allergic rhinitis. Curr Med Res Opin 2004; 20: 1549-1558
43. Wilson AM, Dempsey Of, Sims EJ et al. A comparison of topical budesonide and oral montelukast in seasonal allergic rhinitis and asthma. Clin Exp Allergy 2001; 31: 616-624
44. Kidney J, Dominguez M, Taylor PM et al. Immunomodulation by theophylline in asthma. Demonstration by withdrawal of therapy. Am J Respir Crit Care Med 1995; 151: 1907-1914
45. Tasche MJ, Wouiden JC van der, Uijen JH et al. Randomised placebo-controlled trial of inhaled sodium cromoglycate in 1-4-year-old children with moderate asthma. Lancet 1997; 350 (9084): 1060-1064
46. Tsiu SJ, Self TH;Burns R. Theophylline toxicity: update. Ann Allergy 1990; 64 (2 Pt 2): 241-257
47. Lazarus SC, Boushey HA, Fahy JV et al. Long-acting beta2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial. JAMA 2001; 285: 2583-2593
48. Lemanske RF Jr, Sorkness C, Mauger EA et al. Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol: a randomized controlled trial. JAMA 2001; 285: 2594-2603
49. Woolcock A, Lundback B, Ringdal N et al. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 1996; 153: 1481-1488
50. Pauwels RA, Lofdahl CG, Postma DS et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997; 337: 1405-1411
51. Powell H, Gibson PG. Inhaled corticosteroid doses in asthma: an evidence-based approach. Med J Aust 2003; 178: 223-225
52. Cates CJ, Adams N, Bestall J. Holding chambers versus nebulisers for inhaled steroids in chronic asthma. Cochrane Database Syst Rev 2001; (2): CD001491
53. Price DB, Hernandez D, Magyar P et al. Clinical Outcomes with Montelukast as a Partner Agent to Corticosteroid Therapy (COMPACT) International Study Group. Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma. Thorax 2003; 58: 211-216
54. Evans DJ, Taylor DA, Zetterstrom O et al. A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma. N Engl J Med 1997; 337: 1412-1418
55. Malone R, LaForce C, Nimmagadda S et al. The safety of twice-daily treatment with fluticasone propionate and salmeterol in pediatric patients with persistent asthma. Ann Allergy Asthma Immunol 2005; 95: 66-71
56. Toogood JH, Baskerville JC, Jennings B et al. Influence of dosing frequency and schedule on the response of chronic asthmatics to the aerosol steroid budesonide. J Allergy Immunol 1982; 70: 288-298
57. Vaquerizo MJ, Casan P, Castillo J et al. Effect of montelukast added to inhaled budesonide on control of mild to moderate asthma. Thorax 2003; 58: 204-210
58. Mash B, Bheekie A, Jones PW. Inhaled vs. oral steroids for adults with chronic asthma. Cochrane Databse Syst Rev 2000; 2: CD 002160
59. Ayres JG, Jyothish D, Ninan T. Brittle asthma. Paediatr Respir Rev 2004; 5: 40-44
60. Kroegel C, Foerster M. Omalizumab. In: "Handbook of Therapeutic Antibodies", Dubel S. (Hrsg.), 1. Auflage. Weinheim: Wiley-VCH, 2007; Volume III: S. 534-583
61. Bergmann N, Foerster M, Reissig A et al. Benefits of Interferon-acon-1 (IFN-acon-1) as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy. Results of a 12-month prospective case-controlled study. Eur Resp J 2006; 28 (Suppl 50): 439s
62. Berry MA, Hargadon B, Shelley M et al. Evidence of a role of tumor necrosis factor in refractory asthma. N Engl J Med 2006; 354: 697-708
63. Erin EM, Leaker BR, Nicholson GC et al. The effects of a monoclonal antibody directed against tumor necrosis factor-alpha in asthma. Am J Respir Crit Care Med 2006; 174: 753-762
64. Howarth PH, Babu KS, Arshad HS et al. Tumour necrosis factor (TNF) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax 2005; 60: 1012-1018
65. Kroegel C, Bergmann N, Foerster M et al. Interferon-acon-1 treatment of three patients with severe glucocorticoid-dependent asthma. Effect on disease control and systemic glucocorticosteroid dose. Respiration 2006; 73: 566-570
66. Mock B, Kroegel C, Kugler J. Interferon-alpha treatment in severe persistent bronchial asthma: a meta-analysis. Thorax: in Druck
67. Reddel HK, Barnes DJ. Exacerbation Advisory Panel. Pharmacological strategies for self-management of asthma exacerbations. Eur Respir J 2006; 28: 182-199
68. Bateman ED, Fairall L, Lombardi DM et al. Budesonide/formoterol and formoterol provide similar rapid relief in patients with acute asthma showing refractoriness to salbutamol. Respir Res 2006; 7: 13
69. Nicholson KG, Nguyen-Van-Tam JS, Ahmed AH et al. Randomised placebo-controlled crossover trial on effect of inactivated influenza vaccine on pulmonary function in asthma. Lancet 1998; 351 (9099): 326-331
70. Hawkins G, McMahon AD, Twaddle S et al. Stepping down inhaled corticosteroids in asthma: randomised controlled trial. BMJ 2003; 326 (7399): 1115-1118
71. Boulet LP, Drollmann A, Magyar P et al. Comparative efficacy of once-daily ciclesonide and budesonide in the treatment of persistent asthma. Respir Med 2006; 100: 785-794
72. Masoli M, Weatherall M, Holt S et al. Moderate dose inhaled corticosteroids plus salmeterol versus higher doses of inhaled corticosteroids in symptomatic asthma. Thorax 2005; 60: 730-734
73. Rabe KF, Atienza T, Magyar P et al. Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. Lancet 2006; 368 (9537): 744-753
74. Rabe KF, Pizzichini E, Stallberg B et al. Budesonide/formoterol in a single inhaler for maintenance and relief in mild-to-moderate asthma: a randomized, double-blind trial. Chest 2006; 129: 246-256